CLRB Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
8.1M
+12.6%
7.2M
+24.2%
5.8M
+1.8%
5.7M
+17.3%
4.9M
R&D
5.4M
+19.3%
4.6M
+51.5%
3.0M
-4.8%
3.2M
+25.2%
2.5M
SG&A
2.7M
+1.1%
2.6M
-5.3%
2.8M
+10.1%
2.5M
+8.8%
2.3M
Operating Income
-8104015
-12.6%
-7196012
-24.2%
-5793942
-1.8%
-5690629
-17.3%
-4850696
EBITDA
-8068746
-12.7%
-7160488
-21.3%
-5903960
-4.7%
-5641168
-17.6%
-4798419
Net Income
-7974743
-15.1%
-6930653
-22.6%
-5653946
-6.8%
-5295221
-19.2%
-4443877
EPS (Basic)
$-0.46
+19.3%
$-0.57
+57.1%
$-1.33
-3.9%
$-1.28
+9.2%
$-1.41
EPS (Diluted)
$-0.46
+19.3%
$-0.57
+57.1%
$-1.33
-3.9%
$-1.28
+9.2%
$-1.41
Shares (Diluted)
17.5M
+42.8%
12.2M
+188.5%
4.2M
+2.8%
4.1M
+30.5%
3.2M
Cellectar Biosciences INC NEW (CLRB) — Financials